Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab and Siponimod vs Fingolimod in Pediatric Multiple Sclerosis
NCT04926818Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2021
- Primary completion
- Mar 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 25
01
Overview
Phase 3, randomised, double-blind trial of ofatumumab and siponimod in multiple sclerosis (MS) (3 arms), sponsored by Novartis. Primary endpoint: Annualized relapse rate at 24 months. Started Oct 2021; status: active, not recruiting.
02
Drugs
ofatumumabsiponimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04926818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04926818.